申请人:Leo Pharmaceutical Products Ltd. A/S (L.o slashed.vens Kemiske Fabrik
公开号:US05612325A1
公开(公告)日:1997-03-18
A compound of formula I ##STR1## wherein R stands for a straight or branched, saturated or unsaturated alkyl group containing from 4 to 12 carbon atoms optionally substituted with a hydroxy group, and possibly containing a ring structure, and in which at least one of the carbon atoms not bearing hydroxyl group is substituted with one or more halogen atoms or an azido group; and prodrugs of I in which one or more of the hydroxy groups are masked as groups which can be reconverted to hydroxy groups in vivo, in pure form or in mixtures. The compounds show antiinflammatory and immunomodulating effects as well as strong activity in inducing differentiation and inhibiting undesirable proliferation of certain cells. The compounds are prepared by oxidizing 1(S),3(R)-bis-(tert-butyldimethylsilyloxy)-20(S)formyl-9,10-seco-pregna-5( E),7(E),10(19)-triene, reducing the resulting product; alkylating the reduction product and then subjecting the alkylated product to triplet-sensitized photoisomerization.
一种具有公式I的化合物,其中R代表一个直链或支链、饱和或不饱和的烷基基团,含有4至12个碳原子,可选地取代为一个羟基基团,并且可能含有一个环结构,在其中至少有一个不带羟基基团的碳原子被一个或多个卤原子或偶氮基取代;以及I的前体药物,其中一个或多个羟基被掩蔽为在体内可以重新转化为羟基的基团,可以是纯形式或混合物。这些化合物表现出抗炎和免疫调节作用,以及在诱导细胞分化和抑制某些细胞不良增殖方面的强活性。这些化合物是通过氧化1(S),3(R)-双-(叔丁基二甲基硅氧基)-20(S)甲酰-9,10-去甲孕烷-5(E),7(E),10(19)-三烯,还原所得产物;烷基化还原产物,然后将烷基化产物暴露于三重态敏化光异构化来制备的。